Bart Bergstein, a founder and former managing partner of Forbion Capital Partners, has been appointed chief financial officer of Cellnovo Ltd of the UK, a medical device company that specialises in mobile diabetes management. Cellnovo is a portfolio company of Forbion.
Prior to helping found Forbion, Mr Bergstein was in the private equity department of ABN AMRO where he set up the bank’s life sciences team in 2000. Mr Bergstein holds a masters degree in construction engineering from the Technical University of Eindhoven in the Netherlands.
Cellnovo announced the appointment on 22 April 2014.
Copyright 2014 Evernow Publishing Ltd